The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...

FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial ...

Silexion Therapeutics (SLXN) announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation ...

Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug ...

The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.

The movement of connected cells contributes to morphogenesis, wound healing and cancer invasion and each process underlies homologous but distinct molecular mechanisms of cell–cell interaction ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLA™ (fruquintinib capsules), indicated for the treatment of adult patients with ...

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...